


Below is the Order of the Court.




Marc Barreca

U.S. Bankruptcy Judge

(Dated as of Entered on Docket date above)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18 **UNITED STATES BANKRUPTCY COURT**
19 **WESTERN DISTRICT OF WASHINGTON**
20 **AT SEATTLE**
21

22 In re

23
24 NATURAL MOLECULAR TESTING
25 CORPORATION,

26
27 Debtor.
28
29
30
31

Case No. 13-19298-MLB

ORDER GRANTING SALE OF ASSETS
OUTSIDE THE ORDINARY COURSE OF
BUSINESS (MEDTECH)

32
33 THIS MATTER came before the Court upon the motion of the Chapter 11 Trustee
34 Mark Calvert for an Order Pursuant 11 USC §363 and Bankruptcy Rule 6004 Authorizing
35 and Approving the Sale of the Debtor's Assets Outside of the Ordinary Course of Business
36 for Approval of the Sale of Assets outside the Ordinary Course of Business (the "Sale
37 Motion"). The Court has reviewed the Sale Motion, the Declaration of Mark Calvert in
38 Support of Motion for Sale of Assets, the United States' Objection to the Sale Motion, the
39 Committee's Opposition to the Sale Motion, the Declaration of Christopher M. Alston in
40
41
42
43
44
45
46
47

ORDER GRANTING TRUSTEE'S MOTION FOR
SALE OF ASSETS (MEDTECH) – 1

115286-0001/LEGAL124796044.1

Perkins Coie LLP
1201 Third Avenue, Suite 4900
Seattle, WA 98101-3099
Phone: 206.359.8000
Fax: 206.359.9000

1 Support of the Committee’s Opposition to the Sale Motion, the Purchaser’s Modification of
2 Term Sheet (the “Modification”), the Trustee’s Update Regarding the Sale Motion, the
3 Committee’s Supplemental Response in Support of Opposition to the Sale Motion, the
4 Supplemental Declaration of Mark Calvert in Support of Motion for Sale of Assets, United
5 States’ Supplemental Response in Support of Opposition to the Trustee’s Motion for an
6 Order Authorizing and Approving the Sale of Debtor’s Assets Outside of the Ordinary
7 Course of Business, the Trustee’s Submission of Asset Purchase Agreement, the Declaration
8 and Supplemental Declaration of Beau Fessenden, Committee’s Second Supplemental
9 Response in Support of Opposition to Trustee’s Motion for Order Authorizing and
10 Approving Sale of Debtor’s Assets, United States’ Second Supplemental Response in
11 Support of Opposition to the Trustee’s Motion for an Order Approving the Sale of the
12 Debtor’s Assets Outside of the Ordinary Course of Business, and the Trustee’s Reply in
13 Support of Motion for an Order Pursuant to U.S.C. §363 and Bankruptcy Rule 6004
14 Authorizing and Approving the Sale of the Debtor’s Assets Outside of the Ordinary Course
15 of Business, and has heard the argument of counsel on the record. All capitalized terms not
16 otherwise defined herein shall have the meaning set forth in the Asset Purchase Agreement
17 between the Trustee and MedTech National, Inc. or its assignee (“MedTech”), in the form
18 attached hereto as Exhibit A, as may be amended by this Order (the “MedTech APA”)

36 **THE COURT HERBY FINDS AS FOLLOWS:**

37 A. The findings and conclusions set forth herein constitute this Court’s
38 findings of fact and conclusions of law pursuant to Bankruptcy Rule 7052, made applicable
39 to this proceeding pursuant to Bankruptcy Rule 9014. To the extent any of the following
40 findings of fact constitute conclusions of law, they are adopted as such. To the extent any of
41 the following conclusions of law constitute findings of fact, they are adopted as such.

42
43
44
45
46
47 ORDER GRANTING TRUSTEE’S MOTION FOR
SALE OF ASSETS (MEDTECH) – 2

115286-0001/LEGAL124796044.1

Perkins Coie LLP
1201 Third Avenue, Suite 4900
Seattle, WA 98101-3099
Phone: 206.359.8000
Fax: 206.359.9000

1 B. This Court has jurisdiction over the Sale Motion and the Sale
2 Transaction pursuant to 28 U.S.C. §§ 157 and 1334, and this matter is a core proceeding
3 pursuant to 28 U.S.C. § 157(b)(2)(A), (M) and (O). Venue in this district is proper under 28
4 U.S.C. §§ 1408 and 1409.
5

6
7 C. The statutory predicates for the relief requested in the Sale Motion are
8 Bankruptcy Code Sections 105 and 363 and Bankruptcy Rules 2002, 6004 and 9014.
9

10 D. Proper, timely, adequate, and sufficient notice of the Sale Motion
11 have been provided by the Debtor in accordance with Sections 102(1) and 363(b) of the
12 Bankruptcy Code, Bankruptcy Rules 2002, 6004, 9006, 9007, and 9014, the Local
13 Bankruptcy Rules for the Western District of Washington. Such notice was good and
14 sufficient and appropriate under the circumstances of this case. No other or further notice of
15 the Sale Motion or of the entry of this Order is necessary or shall be required. A reasonable
16 opportunity to object or be heard regarding the requested relief has been afforded to all
17 interested persons and entities.
18

19 E. The Sale Motion sought to sell substantially all of the Debtor's
20 operating assets to YOURCODE, INC. ("YOURCODE"). One of the conditions precedent
21 to such sale was YOURCODE negotiating a new lease with the Debtor's landlord.
22 YOURCODE was unsuccessful in doing so. YOURCODE filed its Modification on
23 December 16, 2014, indicating that YOURCODE was only interested in purchasing certain
24 intellectual property assets and a GMC Sierra truck.
25

26 F. The Trustee filed an Update Regarding the Sale Motion on
27 December 17, 2014 indicating that the Trustee agreed to sell the Debtor's intellectual
28 property assets to YOURCODE pursuant to the terms set forth in the Modification filed by
29

30 ORDER GRANTING TRUSTEE'S MOTION FOR
31 SALE OF ASSETS (MEDTECH) – 3

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

115286-0001/LEGAL124796044.1

Perkins Coie LLP
1201 Third Avenue, Suite 4900
Seattle, WA 98101-3099
Phone: 206.359.8000
Fax: 206.359.9000

1 YOURCODE. At a hearing on December 19, 2014, the Court continued the hearing to
2 January 16, 2015 and set intermediate deadlines.
3

4 G. On January 2, 2015, the Trustee filed a Submission of Asset Purchase
5 Agreement, reflecting the terms under which YOURCODE agreed to purchase specified
6 assets from the Trustee.
7

8 H. The Court conditionally approved the sale pursuant to that Asset
9 Purchase Agreement, subject to further revisions, on January 16, 2015. On January 20,
10 2015, the Trustee submitted a revised Asset Purchase Agreement with YOURCODE [Doc.
11 494] (the “YOURCODE APA”).
12

13 I. On January 16, 2015, MedTech provided the Trustee a draft Asset
14 Purchase Agreement for the Debtor’s laboratory equipment and related assets. Attached
15 hereto as Exhibit A is revised form of Asset Purchase Agreement with MedTech (the
16 “MedTech APA”). There is no overlap in assets sold between the YOURCODE APA and
17 the MedTech APA, but when viewed together the combined purchase of substantially all of
18 the Debtor’s operating assets.
19

20 J. The Assigned Assets to be transferred pursuant to the MedTech APA
21 (the “Assets”) constitute property of the Debtor’s estate and title thereto is vested in the
22 Debtor’s estate within the meaning of § 541(a) of the Bankruptcy Code.
23

24 K. The Trustee has demonstrated a sufficient basis and compelling
25 circumstances for it to sell the Assets under Section 363 of the Bankruptcy Code, and such
26 action is an appropriate exercise of the Trustee’s business judgment and in the best interests
27 of the Debtor, the estate and the creditors. Such business reasons include, but are not limited
28 to, the facts that (i) there is substantial risk of deterioration of the value of the Assets if the
29 Sale is not consummated quickly; (ii) the MedTech APA constitutes the highest or best offer
30

31 ORDER GRANTING TRUSTEE’S MOTION FOR
32 SALE OF ASSETS (MEDTECH) – 4

33 115286-0001/LEGAL124796044.1

34 **Perkins Coie LLP**
35 1201 Third Avenue, Suite 4900
36 Seattle, WA 98101-3099
37 Phone: 206.359.8000
38 Fax: 206.359.9000

1 for the Assets; (iii) and unless the Sale is concluded as provided for in the Sale Motion and
2 pursuant to the MedTech APA, potential creditor recoveries may be substantially
3 diminished.
4

5 L. The Trustee marketed the Assets and conducted the marketing and
6 sale process as set forth in the Sale Motion and the Trustee's supporting declarations.
7

8 M. The Sale transaction has been negotiated by the Trustee and MedTech
9 in good faith, at arms' length and without collusion. The terms and conditions of the
10 MedTech APA, including the total consideration to be realized by the Debtor pursuant to the
11 MedTech APA, are fair and reasonable, and the Sale transaction is in the best interest of the
12 Debtor, its creditors and its estate.
13

14 N. The Trustee and MedTech have not engaged in any conduct that
15 would cause or permit the APA or the consummation of the Sale transactions to be avoided,
16 or costs or damages to be imposed, under Section 363(n) of the Bankruptcy Code.
17

18 O. Sufficient evidence has been provided that the MedTech is acting in
19 good faith pursuant to Section 363(m) of the Bankruptcy Code in consummating the Sale
20 transaction.
21

22 P. MedTech is therefore a "good faith purchaser" entitled to the full
23 benefits and protections of Section 363(m) of the Bankruptcy Code with respect to the
24 purchase and sale of the Assets.
25

26 Q. The sale of the Assets to MedTech will be, as of the Closing, a legal,
27 valid and effective transfer of such Assets, and will vest the MedTech with all right, title and
28 interest of the Debtor to the Assets free and clear of all liens (the "Liens"), with such Liens to
29 attach to the consideration to be received by the Debtor in the same priority and subject to
30 the same defenses and avoidability, if any, as of the Closing. MedTech would not acquire
31
32

33 ORDER GRANTING TRUSTEE'S MOTION FOR
34 SALE OF ASSETS (MEDTECH) – 5
35

1 the Assets if the sale thereof were not free and clear of all Liens. A sale of the Assets other
2 than one free and clear of all Liens would adversely impact the Debtor's estate, and would
3 yield substantially less value for the estate, with less certainty than the Sale. Therefore, the
4 Sale is in the best interests of the Debtor, the estate and creditors, and all other parties in
5 interest.
6
7

8 R. The Debtor may sell and assign the Assets free and clear of all Liens,
9 because, with respect to each creditor asserting a Lien, one or more of the standards set forth
10 in Bankruptcy Code sections 363(f)(1)-(5) has been satisfied. Those holders of Liens who
11 did not object or who withdrew their objections to the Sale are deemed to have consented to
12 the Sale of the Assets to the Purchaser pursuant to Bankruptcy Code section 363(f)(2). The
13 holders of Liens who did object, if any, fall within one or more of the other subsections of
14 Bankruptcy Code section 363(f) and are adequately protected by having their Liens, if any,
15 attach to the proceeds of the Sale ultimately attributable to the Assets in which such holders
16 allege a Lien, in the same order of priority, with the same validity, force and effect that such
17 holder had prior to the Sale, and subject to any claims and defenses the Debtor and its estate
18 may possess with respect thereto.
19
20

21 S. MedTech shall have no obligations with respect to any liabilities of
22 the Debtor other than those liabilities expressly assumed (the "Assumed Liabilities").
23
24

25 T. The Sale transaction contemplated under the MedTech APA does not
26 amount to a consolidation, merger or *de facto* merger of the Purchaser and the Debtor and/or
27 the Debtor's estate; there is not substantial continuity between MedTech and the Debtor,
28 there is no common identity between the Debtor and MedTech, there is no continuity of
29 enterprise between the Debtor and MedTech, and MedTech is not a mere continuation of the
30 Debtor or its estate. Accordingly, MedTech does not constitute a successor to the Debtor or
31
32

33 ORDER GRANTING TRUSTEE'S MOTION FOR
34 SALE OF ASSETS (MEDTECH) – 6

35
Perkins Coie LLP
36 1201 Third Avenue, Suite 4900
37 Seattle, WA 98101-3099
38 Phone: 206.359.8000
39 Fax: 206.359.9000

1 its estate. Other than the Assumed Liabilities, MedTech shall have no obligations with
2 respect to any liabilities of the Debtor.
3

4 U. The consummation of the Sale transaction is legal, valid and properly
5 authorized under all applicable provisions of the Bankruptcy Code, including without
6 limitation Bankruptcy Code §§ 105(a), 363(b), 363(f), 363(m) and all of the applicable
7 requirements of such sections have been or will be complied with in respect of the Sale as of
8 the Closing.
9

10 V. The Sale of the Assets outside of a plan of reorganization pursuant to
11 the MedTech APA neither impermissibly restructures the rights of the Debtor's creditors nor
12 impermissibly dictates the terms of a liquidating plan of reorganization for the Debtor. The
13 Sale transaction does not constitute a *sub rosa* chapter 11 plan.
14

15 W. Time is of the essence. In order to maximize the value of the
16 Debtor's assets, it is essential that the Sale of the Assets occur within the time constraints set
17 forth in the MedTech APA. Accordingly, there is cause to lift the stay contemplated by
18 Bankruptcy Rule 6004(h).
19

20 X. The Sale transaction contemplated by the MedTech APA is in the best
21 interests of the Debtor and its estate, its creditors, interest holders and all other parties in
22 interest herein; and it is therefore,
23

24 **ORDERED, ADJUDGED AND DECREED THAT:**
25

26 1. The relief requested in the Sale Motion is GRANTED, subject to the
27 terms and conditions contained herein.
28

29 2. All objections and responses to the Sale Motion that have not been
30 overruled, withdrawn, waived, settled, continued, or resolved, and all reservations of rights
31 included therein, are hereby overruled and denied.
32

33 **ORDER GRANTING TRUSTEE'S MOTION FOR**
34 **SALE OF ASSETS (MEDTECH) – 7**

35 115286-0001/LEGAL124796044.1

36 **Perkins Coie LLP**
37 1201 Third Avenue, Suite 4900
38 Seattle, WA 98101-3099
39 Phone: 206.359.8000
40 Fax: 206.359.9000

1 3. Notice of the Sale Hearing was fair and equitable under the
2 circumstances and complied in all respects with §102(1) of the Bankruptcy Code and
3 Bankruptcy Rules 2002, 6004 and 9014.

4 4. The Court's findings of fact and conclusions of law on the record are
5 incorporated herein by reference.

6 5. The MedTech APA and the Sale are hereby approved, and the Trustee
7 is hereby authorized and empowered to enter into, and to perform his obligations under, the
8 MedTech APA and to execute and perform such agreements or documents, and take such
9 other actions as are necessary or desirable to effectuate the terms of the MedTech APA.

10 6. MedTech is hereby granted and is entitled to all of the protections
11 provided to a good faith purchaser under section 363(m) of the Bankruptcy Code. Pursuant
12 to section 363(m) of the Bankruptcy Code, if any or all of the provisions of this Order are
13 hereafter reversed, modified or vacated by a subsequent order of this Bankruptcy Court or
14 any other court, such reversal, modification or vacatur shall not affect the validity and
15 enforceability of any sale, transfer or assignment under or pursuant to the MedTech APA, or
16 any obligation or right granted pursuant to the terms of this Order (unless stayed pending
17 appeal), and notwithstanding any reversal, modification or vacatur shall be governed in all
18 respects by the original provisions of this Order or the MedTech APA, as the case may be.

19 7. The Sale as approved by this Order is not subject to avoidance
20 pursuant to section 363(n) of the Bankruptcy Code.

21 8. The Trustee is authorized and empowered, at the Closing, to fully
22 perform under, consummate, and implement the terms of the MedTech APA together with
23 any and all additional instruments and documents that may be reasonably necessary or
24 desirable to implement and effectuate the terms of the MedTech APA, this Order, and the

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
ORDER GRANTING TRUSTEE'S MOTION FOR
SALE OF ASSETS (MEDTECH) – 8

Perkins Coie LLP
1201 Third Avenue, Suite 4900
Seattle, WA 98101-3099
Phone: 206.359.8000
Fax: 206.359.9000

115286-0001/LEGAL124796044.1

1 Sale, and to take all further actions as may reasonably be requested by MedTech for the
2 purpose of assigning, transferring, granting, conveying and conferring to MedTech, or
3 reducing to possession any or all of the Assets, as may be necessary or appropriate to the
4 performance of the Trustee's obligations as contemplated by the MedTech APA, without
5 any further corporate action or orders of the Bankruptcy Court.
6
7

8 9. The Trustee is further authorized and empowered to cause to be filed
10 with the secretary of state of any state or other applicable officials of any applicable
11 governmental units, any and all certificates, agreements, or amendments necessary or
12 appropriate to effectuate the transactions contemplated by the MedTech APA, any related
13 agreements and this Order, and all such other actions, filings, or recordings as may be
14 required or as the Trustee may determine are necessary or appropriate.
15
16

17 10. Effective as of the Closing: (a) except as otherwise set forth herein,
18 the sale and assignment of the Assets by the Trustee to MedTech shall constitute a legal,
19 valid and effective transfer of the Assets notwithstanding any requirement for approval or
20 consent by any person and vests the Purchaser with all right, title and interest of the Debtor
21 in and to the Assets, free and clear of all Liens, pursuant to section 363(f) of the Bankruptcy
22 Code, and (b) the assumption of any Assumed Liabilities by MedTech constitutes a legal,
23 valid and effective delegation of any Assumed Liabilities to MedTech and divests the
24 Debtor and its estate of all liability with respect to any Assumed Liabilities.
25
26

27 11. Except to the extent specifically provided in the MedTech APA, upon
28 the Closing, the Trustee shall be, and hereby is, authorized and empowered, pursuant to
29 sections 105, 363(b) and 363(f) of the Bankruptcy Code, to sell and assign the Assets to
30 MedTech. The sale and assignment of the Assets to the MedTech vests MedTech with all
31 right, title and interest of the Debtor to the Assets free and clear of any and all Liens,
32
33

34 ORDER GRANTING TRUSTEE'S MOTION FOR
35 SALE OF ASSETS (MEDTECH) – 9

36
37
38
39
40
41
42
43
44
45
46
47 115286-0001/LEGAL124796044.1

Perkins Coie LLP
1201 Third Avenue, Suite 4900
Seattle, WA 98101-3099
Phone: 206.359.8000
Fax: 206.359.9000

1 Excluded Liabilities, and other liabilities, and whether imposed by agreement,
2 understanding, law, equity or otherwise, with all such Liens to attach only to the proceeds of
3 the Sale and assignment of the Assets with the same priority, validity, force, and effect as
4 they now have in or against the Assets. Except as set forth herein, the Sale Motion shall be
5 deemed to provide sufficient notice as to the sale and assignment of the Assets free and clear
6 of all Liens, Excluded Liabilities, and other liabilities. Following the Closing, no holder of
7 any Lien on the Assets may interfere with MedTech's use and enjoyment of the Assets
8 based on or related to such Lien, or any actions that the Trustee or Debtor may take in this
9 bankruptcy case and no interested party may take any action to prevent, interfere with or
10 otherwise enjoin consummation of the Sale transaction.

11 12. MedTech has not assumed and is not otherwise obligated for any of
12 the Debtor's liabilities other than the Assumed Liabilities and as otherwise set forth in the
13 MedTech APA and this Order, and the Purchaser has not acquired any of the Excluded
14 Assets (as defined in the MedTech APA). Consequently, all persons and all holders of Liens
15 or claims of any kind, including but not limited to claims related to product liability or
16 personal injury, based upon or arising out of liabilities retained by the Debtor are hereby
17 enjoined from taking any action against the MedTech or the Assets, including asserting any
18 setoff, right of subrogation or recoupment of any kind, to recover any Liens or claims of any
19 kind including but not limited to claims related to product liability or personal injury, or on
20 account of any liabilities of the Debtor other than Assumed Liabilities pursuant to the
21 MedTech APA. All persons holding or asserting any Lien on the Excluded Assets are
22 hereby enjoined from asserting or prosecuting such Liens or cause of action against
23 MedTech or the Assets for any liability associated with the Excluded Assets. All persons
24 holding or asserting any claims against Excluded Liabilities are hereby enjoined from
25

26 ORDER GRANTING TRUSTEE'S MOTION FOR
27 SALE OF ASSETS (MEDTECH) – 10

28 115286-0001/LEGAL124796044.1

29 **Perkins Coie LLP**
30 1201 Third Avenue, Suite 4900
31 Seattle, WA 98101-3099
32 Phone: 206.359.8000
33 Fax: 206.359.9000

1 asserting or prosecuting such claims or causes of action against Purchaser or the Assets for
2 any liability associated with the Excluded Liabilities.
3

4 13. The provisions of this Order authorizing the sale and assignment of
5 the Assets free and clear of Liens and the Excluded Liabilities, shall be self-executing, and
6 neither the Trustee, the Debtor nor MedTech shall be required to execute or file releases,
7 termination statements, assignments, consents, or other instruments in order to effectuate,
8 consummate and implement the provisions of this Order.
9

10 14. Each and every federal, state, and local governmental agency or
11 department is hereby authorized to accept any and all documents and instruments necessary
12 and appropriate to consummate the transactions contemplated by the MedTech APA and this
13 Order.
14

15 15. All of the Debtor's interests in the Assets to be acquired by the
16 MedTech under the MedTech APA shall be, as of and upon the occurrence of the Closing,
17 transferred to and vested in the Purchaser.
18

19 16. MedTech is not and shall not be deemed a "successor" to the Debtor
20 or its estate as a result of the consummation of the Sale contemplated by the MedTech APA
21 or any other event occurring in the chapter 11 case under any theory of law or equity, and
22 MedTech shall not assume, nor be deemed to assume, or in any way be responsible for any
23 liability or obligation of any of the Debtor and/or its estate including, but not limited to, any
24 bulk sales law, successor liability, liability or responsibility for any claim against the Debtor
25 or against an insider of the Debtor, or similar liability except as otherwise expressly
26 provided in the MedTech APA. The sale and assignment of the Assets or the assumption
27 and assignment of the Assumed Liabilities by MedTech and the Sale approved hereby, will
28 not cause the Purchaser to be deemed a successor in any respect to the Debtor.
29

30 ORDER GRANTING TRUSTEE'S MOTION FOR
31 SALE OF ASSETS (MEDTECH) – 11

32 115286-0001/LEGAL124796044.1

33 **Perkins Coie LLP**
34 1201 Third Avenue, Suite 4900
35 Seattle, WA 98101-3099
36 Phone: 206.359.8000
37 Fax: 206.359.9000

1 17. This Order and the MedTech APA shall be binding upon, inure to the
2 benefit of and govern the acts of all persons and entities, including without limitation, the
3 Debtor, the Trustee and the Purchaser, their respective successors and permitted assigns,
4 including, without limitation, any trustee appointed in a chapter 7 case if this case is
5 converted from chapter 11, all creditors of the Debtor (whether known or unknown), filing
6 agents, filing officers, title agents, recording agencies, secretaries of state, and all other
7 persons and entities who may be required by operation of law, the duties of their office or
8 contract, to accept, file, register, or otherwise record or release any documents or
9 instruments or who may be required to report or insure any title in or to the Assets.
10

11 18. The automatic stay pursuant to section 362 of the Bankruptcy Code is
12 hereby lifted, to the extent necessary, without further order of this court to allow MedTech
13 to deliver any notice provided for in the MedTech APA and allow MedTech to take any and
14 all actions permitted under the MedTech APA in accordance with the terms and conditions
15 thereof.

16 19. The Court makes no findings or order with respect to the assignability
17 of any licensed intellectual property used by the Debtor that requires the consent of the
18 licensor to assign, and the rights of any such licensor remain unaffected by this Order.
19 MedTech shall bear all risk that any of the Assets may violate the rights of any such
20 licensor.

21 20. This Bankruptcy Court shall retain exclusive jurisdiction to enforce
22 the terms and provisions of this Order and the MedTech APA in all respects and to decide
23 any disputes concerning this Order, the MedTech APA, or the rights and duties of the parties
24 hereunder or thereunder or any issues relating to the MedTech APA or this Order including,
25 but not limited to, the interpretation of the terms, conditions and provisions hereof and
26

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
ORDER GRANTING TRUSTEE'S MOTION FOR
SALE OF ASSETS (MEDTECH) – 12

Perkins Coie LLP
1201 Third Avenue, Suite 4900
Seattle, WA 98101-3099
Phone: 206.359.8000
Fax: 206.359.9000

115286-0001/LEGAL124796044.1

1 thereof, the status, nature and extent of the Assets and all issues and disputes arising in
2 connection with the relief authorized herein, inclusive of those concerning the transfer of the
3 assets free and clear of all Liens.
4

5 // END OF ORDER //

6
7 Presented by:
8

9
10 **PERKINS COIE LLP**
11

12
13 By: /s/ John S. Kaplan
14 John S. Kaplan, WSBA No. 23788
15 JKaplan@perkinscoie.com
16 1201 Third Avenue, Suite 4900
17 Seattle WA 98101-3099
18 Telephone: 206.359.8000
19 Facsimile: 206.359.9000
20

21 Attorneys for Trustee Mark Calvert
22

23
24 Approved as Form; Notice of Presentment
25 Waived by:

26
27 **LAW OFFICES OF JACK ORR**
28

29
30 By: _____
31 Jack Orr, WSBA No. 6807
32

33 Attorneys for MedTech National, Inc.
34

35
36 **FOSTER PEPPER PLLC**
37

38
39 By: _____
40 Christopher M. Alston, WSBA No. 18823
41 Jane Pearson, WSBA No. 12785
42

43 Counsel for the Official Unsecured Creditors'
44 Committee
45

46
47 ORDER GRANTING TRUSTEE'S MOTION FOR
SALE OF ASSETS (MEDTECH) – 13

115286-0001/LEGAL124796044.1

Perkins Coie LLP
1201 Third Avenue, Suite 4900
Seattle, WA 98101-3099
Phone: 206.359.8000
Fax: 206.359.9000

1 **ANNETTE L. HAYES**
2 **ACTING UNITED STATES ATTORNEY**
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

By: _____
Christina Fogg, WSBA No. 40159

ORDER GRANTING TRUSTEE'S MOTION FOR
SALE OF ASSETS (MEDTECH) – 14

115286-0001/LEGAL124796044.1

Perkins Coie LLP
1201 Third Avenue, Suite 4900
Seattle, WA 98101-3099
Phone: 206.359.8000
Fax: 206.359.9000

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

. EXHIBIT A

ASSET PURCHASE AGREEMENT

ORDER GRANTING TRUSTEE'S MOTION FOR
SALE OF ASSETS (MEDTECH) – 15

115286-0001/LEGAL124796044.1

Perkins Coie LLP
1201 Third Avenue, Suite 4900
Seattle, WA 98101-3099
Phone: 206.359.8000
Fax: 206.359.9000

ASSET PURCHASE AGREEMENT

THIS ASSET PURCHASE AGREEMENT, dated as of January 27, 2015 (the "Agreement"), is made by and among Mark Calvert, in his capacity as Chapter 11 Trustee (the "Trustee") for Natural Molecular Testing Corporation, a Washington corporation ("Seller"), and MedTech National, Inc., a Washington corporation, or its assignee, which must have a minimum equity of One Million Dollars (\$1,000,000) ("Purchaser"). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in Article 9 of this Agreement.

WHEREAS, on October 21, 2013 (the "Petition Date"), Seller sought relief under Chapter 11 of Title 11 of the United States Code (the "Bankruptcy Code") by filing a case, entitled In re Natural Molecular Testing Company, Case No. 13-19298 (the "Bankruptcy Case") in the United States Bankruptcy Court for the Western District of Washington (the "Bankruptcy Court");

WHEREAS, by order of the Bankruptcy Court dated September 29, 2014, the Trustee was appointed as Chapter 11 trustee for Seller;

WHEREAS, Seller intends to sell certain assets and properties pursuant to, inter alia, Sections 105, 363 and 365 of the Bankruptcy Code;

WHEREAS, Purchaser desires to purchase certain assets and properties of Seller and Seller desires to sell, convey, assign and transfer to Purchaser pursuant to, inter alia, Sections 105, 363 and 365 of the Bankruptcy Code, those certain assets and properties all in the manner and subject to the terms and conditions set forth herein; and

NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements set forth herein, the parties hereto agree as follows:

ARTICLE 1. PURCHASE AND SALE OF ASSETS

SECTION 1.01 *Acquired Assets*

Subject to the terms and conditions set forth in this Agreement and subject to the approval of the Bankruptcy Court, and pursuant to the Sale Order, at the Closing, Seller shall transfer, assign, convey and deliver to Purchaser or its designee, pursuant to Section 363 of the Bankruptcy Code, all of the Acquired Assets, free and clear of liens as provided in the Sale Order.

(a) *Acquired Assets.* On the terms and subject to the conditions precedent set forth in this Agreement, Seller shall sell, assign, transfer, convey, and deliver (or cause to be sold, assigned, transferred, conveyed and delivered) to Purchaser, and Purchaser shall purchase and accept from Seller, at the Closing all of Seller's rights, title, and interests in, to and under all of the assets, property, rights and claims of Seller relating to all of its assets identified on Exhibit A hereto. In addition to the assets set forth on Exhibit A, Purchaser desires to purchase, and Trustee will attempt to sell to Purchaser, one Roche MagnaPure Extractor (the "MagnaPure") for a promissory note for \$50,000; however the MagnaPure will only be added to the Acquired

Assets upon entry of a separate order of the Bankruptcy Court approving such sale, and the Sale will close without inclusion of the MagnaPure if the Trustee is unable to obtain such an order despite reasonable efforts. The transfer of the Acquired Assets shall be "as is, where is, with Purchaser bearing the cost of re-locating the Acquired Assets to Purchaser's desired location.

(b) *Excluded Assets.* Notwithstanding the foregoing, Purchaser expressly understands and agrees that (a) the assets and properties of Seller listed on Exhibit B under the heading "Excluded Assets" (as amended from time to time by Purchaser prior to Closing) shall be excluded from the Acquired Assets.

SECTION 1.02 *Assumed Liabilities.* On the terms and subject to the conditions set forth in this Agreement, at the Closing, Purchaser shall assume from Seller and thereafter pay, perform or discharge when due (or cause to be paid, performed or discharged when due) in accordance with their terms all of Seller's liabilities and obligations arising or otherwise relating to any period on or after the Closing Date the liabilities expressly set forth on Exhibit C. The liabilities to be assumed pursuant to this Section 1.02 shall be referred to herein as the "**Assumed Liabilities**".

SECTION 1.03 *Excluded Liabilities.* Notwithstanding any other provision of this Agreement to the contrary, Purchaser is assuming only the Assumed Liabilities and is not assuming any other liability or obligation of Seller of any nature, whether presently in existence or arising hereafter, known or unknown, disputed or undisputed, contingent or noncontingent, liquidated or unliquidated or otherwise, including severance, termination pay, accrued vacation, pension, profit sharing or any other employee benefit plans, compensation or retiree medical or other benefits and obligations, or any obligation, claim or amount for employees, or any obligation, claim or amount under the Workers Adjustment and Retraining Notification Act ("WARN Act") or COBRA, product related liabilities of Seller or liabilities arising under environmental laws. All such other liabilities and obligations shall be retained by and remain obligations and liabilities of Seller (all such liabilities and obligations not being assumed being herein referred to as the "**Excluded Liabilities**").

SECTION 1.04 *Purchase Price.* The consideration for the Acquired Assets shall consist of the following (together, the "**Purchase Price**"):

(a) Cash of \$25,000, payable upon Court Approval and non-refundable upon the Sale Order becoming a Final Order;

(b) A Promissory Note (the "**Promissory Note**") in the principal amount of \$285,000 bearing interest at six percent (6%) per annum, payable in 40 monthly installments of principal and interest in the amount of \$8,500, plus a final payment of \$3,415, pursuant to the amortization schedule set forth on Schedule 1.04(b). There shall be no prepayment penalty. The Purchaser's obligations under the Promissory Note will be secured by the assets of the Purchaser acquired from the Seller under this Agreement pursuant to a Security Agreement (the "**Security Agreement**");

(c) Release of any and all claims MedTech National, Inc., may have against Seller of any nature, including without limitation the waiver of any administrative claim in the Bankruptcy Case, said claims being estimated by Purchaser to be \$450,000; and

(d) Payment to Seller of a royalty (the “**Royalty**” or “**Royalties**”) in the amount of five percent (5%) of Purchaser’s gross revenues received from Laboratory Operations during the five (5) calendar years after Closing, payments of the Royalty to be made to the Seller on or before the 15th day of each month, based on the Purchaser’s revenues for the prior month. Such payment shall be accompanied by a report of the revenues upon which the Royalties are based, in sufficient detail as reasonably requested by the Seller. Provided, in no event shall Purchaser be required to pay Seller more than Two Million Dollars (\$2,000,000) in Royalties in any calendar year or Ten Million dollars (\$10,000,000) in Royalties in the aggregate. When Purchaser has paid Seller ten million dollars (\$10,000,000) in the aggregate in Royalties, Purchaser’s obligation to pay Royalties shall have been satisfied in full and Purchaser will no longer be obligated to pay any further Royalties to Seller. Seller shall have the right to an annual audit or other review of Purchaser’s financial records to determine to Seller’s reasonable satisfaction that Purchaser’s calculation of the amount of Royalties due and paid to Seller is correct.

Purchaser shall pay the cash portion of the Purchase Price at Closing by wire transfer pursuant to instructions provided by Seller to Purchaser.

SECTION 1.05 *Transfer Taxes.* Purchaser will be responsible for and timely pay (without adjustment to the Purchase Price) any sales, use or transfer Taxes, documentary charges, recording fees, or similar Taxes, charges or fees arising from or in connection with the sale, assignment and transfer of the Acquired Assets to Purchaser pursuant to this Agreement.

SECTION 1.06 *Allocation.* On or prior to the Closing, Purchaser and Seller shall prepare an allocation of the Purchase Price among the Acquired Assets in accordance with Section 1060 of the Internal Revenue Code, as amended, and the Treasury Regulations thereunder (and any similar state or local law, as appropriate), and attach such allocation to this Agreement as Schedule 1.06. Purchaser and Seller will file IRS Form 8594 and all tax returns in a manner that is consistent with the allocation of the Purchase Price and the Assumed Liabilities among the Acquired Assets, as set forth on the agreed Schedule 1.06.

ARTICLE 2. THE CLOSING

SECTION 2.01 *Closing.* The consummation of the transactions contemplated by this Agreement (the “**Closing**”) shall take place at the offices of Perkins Coie LLP, 1201 Third Avenue, Suite 4800, Seattle, Washington, 98101-3099, at 10:00 a.m. (Seattle time) (a) no later than the fifteenth day after the Sale Order becomes a Final Order (unless the requirement of a Final Order is waived by Purchaser) and all of the conditions set forth in Article 6 shall have been satisfied or waived (other than conditions with respect to actions the parties will take at the Closing itself), or (b) at such other time, date and place as shall be fixed by agreement among the parties (the date of the Closing being herein referred to as the “**Closing Date**”).

SECTION 2.02 *Deliveries at Closing.*

(a) At the Closing, Seller shall deliver to Purchaser:

(i) a duly executed bill of sale, assignment and assumption with respect to the Acquired Assets and the Assumed Liabilities (the “**Bill of Sale**”), substantially in the form attached hereto as Exhibit D, transferring the Acquired Assets to Purchaser free and clear of any and all liens;

(ii) such further deeds, bills of sale, assignments of leases and contracts, and any other instruments of conveyance (collectively, the “**Conveyance Documents**”) as are reasonably deemed necessary or appropriate by Purchaser to effectuate the assignment of the Acquired Assets by Seller and effectively vest in Purchaser good, valid and marketable title to the Acquired Assets; and

(iii) other customary (for transactions of this kind) closing documents, instruments or certificates required to be delivered as a condition precedent to Purchaser’s obligations under this Agreement.

(b) At the Closing, Purchaser shall deliver to Seller:

(i) duly executed instruments as are reasonably deemed necessary or appropriate by Seller to effectuate the assumption of the Assumed Liabilities by Purchaser; and

(ii) other customary closing documents, instruments or certificates required to be delivered as a condition precedent to Seller’s obligations under this Agreement.

(c) At the Closing, Purchaser shall deliver the cash portion of the Purchase Price, the Promissory Note, and the Security Agreement.

SECTION 2.03 *Further Assurances.* After the Closing each party will from time to time, at the reasonable request of the other party, execute and deliver such other instruments of conveyance and transfer and such other instruments, documents and agreements and take such other actions as such other party may reasonably request, in order to more effectively consummate the transactions contemplated hereby and to vest in Purchaser the right, title and interest in, to and under the Acquired Assets and to provide for the assumption of the Assumed Liabilities.

SECTION 2.04 *Compliance with Applicable Law.* Except for the obligations of Seller specifically incurred herein, it shall be Purchaser’s sole responsibility to ensure that the transactions contemplated by this Agreement comply with all applicable law, and Seller makes no representations or warranties regarding such compliance.

ARTICLE 3. REPRESENTATIONS AND WARRANTIES OF SELLER

As of the date hereof, Seller hereby represents and warrants to Purchaser as follows:

SECTION 3.01 *Organization.* Seller is a corporation duly organized and validly existing under the laws of the jurisdiction of its formation. Seller has no subsidiaries.

SECTION 3.02 *Authority.* Subject to the approval of the Bankruptcy Court, the Trustee on behalf of Seller has full corporate capacity, power and authority to enter into this Agreement, to perform its obligations hereunder and to consummate the transactions contemplated hereby in accordance with the terms of this Agreement. This Agreement has been duly executed and delivered by Seller. Assuming due authorization, execution and delivery by Purchaser, this Agreement will constitute a valid and binding obligation of Seller upon the entry of the Sale Order by the Bankruptcy Court.

SECTION 3.03 *Sale Free and Clear*

Except as otherwise disclosed herein, upon entry of the Sale Order, none of the Acquired Assets will be subject to any liens, other than the Assumed Liabilities.

SECTION 3.04 *Assets.*

(a) Except as set forth in Schedule 3.04(a):

(i) Seller owns or has the valid right to use the Acquired Assets;

(ii) no claims have been asserted against Seller by any Person challenging the ownership or right to use any of the Acquired Assets; and

(iii) the ownership and use by Seller of the Acquired Assets does not infringe the rights of any third party.

(b) Except as set forth on Schedule 3.04(b), Seller is not aware of any defenses which a party may have to the assignment or sale of the Acquired Assets to Purchaser.

SECTION 3.05 *Brokers.* No Person is entitled to any brokerage, financial advisory, finder's or similar fee or commission payable in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller.

ARTICLE 4. REPRESENTATIONS AND WARRANTIES OF PURCHASER

Purchaser represents and warrants to Seller as follows:

SECTION 4.01 *Organization.* Purchaser is a corporation that is validly existing and in good standing under the laws of its jurisdiction of organization and has the corporate power and authority to execute and deliver this Agreement and to complete the transactions contemplated by this Agreement.

SECTION 4.02 *Authority.* Purchaser has the power and authority to enter into this Agreement and to carry out its obligations hereunder. The execution, delivery, and

performance of this Agreement by Purchaser and the consummation by Purchaser of the transactions contemplated hereby will have been duly authorized by all requisite corporate action. This Agreement has been duly and validly executed and delivered by Purchaser and (assuming this Agreement constitutes a valid and binding obligation of Seller) constitutes a valid and binding agreement of Purchaser, enforceable against Purchaser in accordance with its terms.

SECTION 4.03 *Consents and Approvals.* Except approvals or authorizations which may be required under the Bankruptcy Code, no consent, approval, certificate, license, permit, waiver, authorization of, or declaration, filing or registration with, any third party or any Governmental Entity is required to be obtained or made by Purchaser in connection with the execution, delivery and performance by Purchaser of this Agreement or the consummation by Purchaser of the transactions contemplated hereby.

SECTION 4.04 *No Violation.* Neither the execution or delivery of this Agreement nor the consummation of the transactions contemplated hereby will, upon entry of the Sale Order: (a) violate any provision of the articles of incorporation or by-laws of Purchaser; or (b) violate any statute, law, judgment, decree, order, regulation or rule of any court or governmental authority applicable to Purchaser; or (c) violate, or be in conflict with, or constitute a default (or an event which, with notice or lapse of time or both, would constitute a default) under, or result in the termination of, or accelerate the performance required by, or cause the acceleration of the maturity of any debt or obligation pursuant to, any agreement or commitment to which Purchaser is a party or by which Purchaser is bound.

SECTION 4.05 *Brokers.* No Person is entitled to any brokerage, financial advisory, finder's or similar fee or commission payable in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Purchaser.

ARTICLE 5. COVENANTS

SECTION 5.01 *Confidentiality.*

(a) Seller covenants that, after the Closing, it will not, without the prior written consent of Purchaser, disclose to any Person confidential information relating to or concerning officers, directors, employees, advisors and representatives who need to know such information for purposes of taxes, accounting, legal and other matters necessary by reason of Seller's ownership, prior to the Closing Date, of the Acquired Assets.

(b) The restrictions and prohibitions set forth in subsection (a) above will not apply to Confidential Information that (i) is known by the receiving party at the time of its receipt, other than through a disclosure by Seller not otherwise permitted under this Section 5.01, (ii) at the time of disclosure is already available in the public domain other than as a result of a breach of this Section 5.01, (iii) is disclosed by Seller in order to perform its obligations or enforce its rights under this Agreement (provided that such disclosure entails only the minimum information required to be disclosed in order to perform their obligations or enforce their rights under this Agreement), or (iv) is required to be disclosed by applicable

law or judicial order (provided that such disclosure entails only the minimum information required to be disclosed in order to comply with the law or order).

(c) This Section 5.01 will survive for a period of one year after the Closing.

SECTION 5.02 *Additional Matters.* Subject to the terms and conditions herein, except as provided by the Bankruptcy Code, the Bankruptcy Rules or any other orders entered or approvals or authorizations granted by the Bankruptcy Court in the Bankruptcy Case, including any order contemplated by Section 6.01(a) hereof, each of the parties hereto agrees to use all commercially reasonable efforts to take, or cause to be taken, all action and to do, or cause to be done, all things necessary, proper or advisable, including under applicable laws and regulations, to consummate and make effective the transactions contemplated by this Agreement, including using all commercially reasonable efforts to obtain all necessary waivers, consents and approvals required under this Agreement.

SECTION 5.03 *Consents; Assignments.* Neither Seller nor Purchaser are aware of any licenses or other contracts that require consent to be assigned to Purchaser with respect to the Acquired Assets, and the Purchaser assumes all risk and expense with respect to any such required consents that are not obtained.

SECTION 5.04 *Disclosure Supplements.* Seller will deliver, and from time to time prior to the Closing Seller shall promptly supplement or amend, the Schedules referred to in Article 3 (the “**Disclosure Schedules**”) with respect to any matter arising after the date hereof which, if existing or occurring at or prior to the date hereof, would have been required to be set forth or described in the Disclosure Schedules or which is necessary to complete or correct any information in the Disclosure Schedules or in any representation or warranty of Seller which has been rendered inaccurate thereby. Each supplement to the Disclosure Schedules provided to Purchaser after execution of this Agreement, shall be clearly labeled as “**Updated Disclosure**”. Within five (5) Business Days of receipt of an Updated Disclosure, Purchaser may, in its sole discretion, either (i) accept the Updated Disclosure, in which case, the event, fact or circumstance so disclosed, shall be deemed to be added to the Disclosure Schedules and shall not be deemed a breach of the representations and warranties of Seller; or (ii) elect to terminate this Agreement. If Purchaser does not notify Seller of its election to terminate this Agreement within five (5) Business Days of receipt of an Updated Disclosure, it shall be deemed to be added to the Disclosure Schedule and shall not be deemed a breach of the representations and warranties of Seller.

ARTICLE 6. CONDITIONS PRECEDENT

SECTION 6.01 *Conditions Precedent to Obligation of Seller and Purchaser.* The respective obligations of each party to effect the transactions contemplated by this Agreement shall be subject to the satisfaction of the following conditions:

(a) all other authorizations, consents, orders and approvals of Governmental Entities and the Bankruptcy Court necessary for the consummation of the transactions contemplated by this Agreement shall have been obtained, including an order from the Bankruptcy Court (the “**Sale Order**”) in a form reasonably satisfactory to Purchaser and which shall, among other

things, (i) contain findings of fact and rulings that Purchaser (A) is a good faith purchaser, (B) is not a successor to the liabilities of Seller, other than the Assumed Liabilities, and (C) is entitled to all applicable protections of the Bankruptcy Code; and (ii) terminate and release all of the liens, claims and interests in and to the Acquired Assets except to the extent securing any of the Assumed Liabilities (it being understood that such order or an abstract thereof shall be in form suitable for filing in applicable lien records and shall direct the execution of appropriate title transfers and lien releases by creditors with respect to the transferred or released property and limitations on the Assumed Liabilities as set forth in this Agreement and enjoin any holder of a claim or interest in Seller from asserting any such claim or interest against Purchaser, other than claims directly related to the Assumed Liabilities);

(b) there shall not be any statute, rule or regulation, enjoining or prohibiting the consummation of the Closing and no court of competent jurisdiction shall have issued, and there shall not have been commenced and be continuing any action by any Governmental Entity seeking, any order, decree or ruling enjoining or prohibiting the consummation of the Closing; and

(c) the Sale Order shall be a Final Order.

SECTION 6.02 *Conditions Precedent to Obligation of Seller.* The obligation of Seller to effect the transactions contemplated by this Agreement shall be subject to the satisfaction or waiver at or prior to the Closing Date of the following additional conditions:

(a) Purchaser shall have performed in all material respects its obligations under this Agreement required to be performed by Purchaser at or prior to the Closing Date; and

(b) the representations and warranties of Purchaser contained in this Agreement shall be true and correct in all respects (in the case of any representation or warranty qualified as to materiality) or all material respects (in the case of any representation or warranty not so qualified) as of the Closing Date as if made at and as of such date except as otherwise contemplated by this Agreement.

SECTION 6.03 *Conditions Precedent to Obligation of Purchaser.* The obligation of Purchaser to effect the transactions contemplated by this Agreement shall be subject to the satisfaction or waiver at or prior to the Closing Date of the following additional conditions:

(a) The sale and purchase of the Acquired Assets shall have been approved by the Bankruptcy Court.

(b) The Sale Order shall, among other things—

- (i) waive the Bankruptcy Rule 6004(h) waiting period;
- (ii) be a Final Order; or, if appealed, and
- (iii) not be subject to any stay.

(c) The representations and warranties of Seller contained in this Agreement shall be true and correct in all respects (in the case of any representation or warranty qualified as to materiality) or all material respects (in the case of any representation or warranty not so qualified) as of the Closing Date as if made at and as of such date except as otherwise contemplated by this Agreement.

ARTICLE 7. TERMINATION, AMENDMENT AND WAIVER

SECTION 7.01 *Termination.* This Agreement may be terminated:

(a) by mutual written agreement of Seller and Purchaser prior to the Closing Date;

(b) at any time before the Closing, by Purchaser if any of the material conditions set forth in Section 6.01 or Section 6.03 shall have become incapable of fulfillment or cure and shall not have been waived by Purchaser, provided that Purchaser is not then in breach of this Agreement; and

(c) at any time before the Closing, by Seller if any of the material conditions set forth in Section 6.01 or Section 6.02 shall have become incapable of fulfillment or cure and shall not have been waived by Seller, provided that Seller is not then in breach of this Agreement.

SECTION 7.02 *Effect of Termination.* If this Agreement is terminated under Section 7.01, written notice thereof will forthwith be given to the other party and this Agreement will thereafter become void and have no further force and effect and, except for those provisions that expressly survive the termination of this Agreement, all further obligations of Seller and Purchaser to each other under this Agreement will terminate without further obligation or liability of Seller or Purchaser to the other, except that each party will return the earnest money paid, all documents, work papers and other material of the other party relating to the transactions contemplated by this Agreement, whether so obtained before or after the execution of this Agreement, to the party furnishing the same.

ARTICLE 8. GENERAL PROVISIONS

SECTION 8.01 *Survival of Representations, Warranties and Covenants.* The representations and warranties in this Agreement shall survive until the Closing. Each of the covenants and obligations of Purchaser and Seller in this Agreement shall survive in accordance with their respective terms.

SECTION 8.02 *Notices.* All notices, claims, demands and other communications hereunder shall be in writing and shall be deemed given upon (a) confirmation of receipt of a facsimile transmission, (b) confirmed delivery by a standard overnight carrier or when delivered by hand, or (c) confirmed delivery by email, in each such case addressed to the respective parties at the following addresses (or such other address for a party as shall be specified by like notice):

(a) If to Purchaser, to

MedTech National, Inc.
1102 Commerce St., 5th Floor
Tacoma, WA 98402
Email: Kirk@medtechnational.com

Such address to be reasonably supplemented prior to closing
with a copy (which shall constitute notice) to:

Jack G. Orr
Law Offices of Jack G. Orr, Inc.
2610 N Alder Street
Tacoma, WA 98407
Fax: 866.476.0889
Email: jackorr@msn.com

(b) If to Seller, to:

Mark Calvert
Trustee for Natural Molecular Testing Corporation
1420 Fifth Avenue, Suite 2211
Seattle, WA 98101
Fax: (206) 642-8200
Email: mark@cascadecapitalgroup.com

with a copy (which shall not constitute notice) to:

Perkins Coie LLP
1201 Third Avenue, Suite 4900
Seattle, WA 98101-3099
Attention: John S. Kaplan
Fax: (206) 359-9408
Email: JKaplan@perkinscoie.com

SECTION 8.03 *Descriptive Headings; Certain Terms.* The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. All references to "\$" or dollars shall be to United States dollars.

SECTION 8.04 *Entire Agreement, Assignment.* This Agreement (including the Exhibits, Schedules and the other documents and instruments referred to herein) constitutes the entire agreement and supersedes all other prior agreements and understandings, both written and oral, between the parties or either of them. Seller and Purchaser acknowledge that in deciding to enter into this Agreement and to consummate the transactions contemplated hereby, they have not relied upon any statements, promises or representations, written or oral, express or implied, other than those explicitly set forth in this Agreement. In furtherance and not in limitation of the foregoing, Purchaser acknowledges that Seller has not made any representations or warranties, of

any kind, either express or implied, except as expressly set forth in this Agreement. PURCHASER ACKNOWLEDGES AND AGREES THAT ALL ACQUIRED ASSETS ARE SOLD "AS IS, WHERE IS", AND THAT THE REPRESENTATIONS AND WARRANTIES GIVEN HEREIN BY SELLER ARE IN LIEU OF, AND PURCHASER HEREBY EXPRESSLY WAIVES ALL RIGHTS TO, ANY IMPLIED WARRANTIES WHICH MAY OTHERWISE BE APPLICABLE BECAUSE OF THE PROVISIONS OF THE UNIFORM COMMERCIAL CODE OR ANY OTHER STATUTE, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. This Agreement shall not be assigned by operation of law or otherwise.

SECTION 8.05 *Governing Laws.* This Agreement shall be governed by and construed in accordance with the laws of the State of Washington without regard to the rules of conflict of laws of the State of Washington or any other jurisdiction. Purchaser and Seller irrevocably and unconditionally consent to submit to the jurisdiction of the Bankruptcy Court for all matters not to commence any litigation relating thereto except in the Bankruptcy Court).

SECTION 8.06 *Expenses.* Except as set forth in this Agreement, whether or not the transactions contemplated by this Agreement are consummated, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such expenses. The foregoing shall not affect the legal right, if any, that any party hereto may have to recover expenses from any other party that breaches its obligations hereunder.

SECTION 8.07 *Amendment.* This Agreement and the Exhibits and Schedules hereto may not be amended except by an instrument in writing signed on behalf of the parties hereto.

SECTION 8.08 *Waiver.* At any time prior to the Closing Date, the parties hereto may (a) extend the time for the performance of any of the obligations or other acts of the other parties hereto, (b) waive any inaccuracies in the representations and warranties contained herein or in any document delivered pursuant hereto, and (c) waive compliance with any of the agreements or conditions contained herein. Any agreement on the part of a party hereto to any such extension or waiver shall be valid only if set forth in an instrument in writing signed on behalf of such party.

SECTION 8.09 *Counterparts; Effectiveness.* This Agreement may be executed by electronic or facsimile signature and in two or more counterparts, each of which shall be deemed to be an original but all of which shall constitute one and the same agreement. This Agreement shall become effective when each party hereto shall have received counterparts thereof signed by the other party hereto.

SECTION 8.10 *Severability; Validity; Parties of Interest.* If any provision of this Agreement or the application thereof to any Person or circumstance is held invalid or unenforceable, the remainder of this Agreement, and the application of such provision to other Persons or circumstances, shall not be affected thereby, and to such end, the provisions of this Agreement are agreed to be severable. Nothing in this Agreement, express or implied, is

intended to confer upon any Person not a party to this Agreement any rights or remedies of any nature whatsoever under or by reason of this Agreement.

SECTION 8.11 *Attorneys' Fees.* In any litigation to enforce the terms of this Agreement, the prevailing party shall be entitled to its reasonable attorneys' fees and costs.

ARTICLE 9. DEFINITIONS

SECTION 9.01 *Defined Terms.* As used in this Agreement (including its Exhibits and Schedules), the terms below shall have the following meanings:

“**Acquired Assets**” has the meaning set forth in Section 1.01(a) and includes, without limitation, the Acquired Assets identified on Exhibit A.

“**Agreement**” has the meaning set forth in the Preamble.

“**Bankruptcy Case**” has the meaning set forth in the Recitals.

“**Bankruptcy Code**” has the meaning set forth in the Recitals.

“**Bankruptcy Court**” has the meaning set forth in the Recitals.

“**Bankruptcy Rules**” means the Federal Rules of Bankruptcy Procedures, as amended.

“**Bill of Sale**” has the meaning set forth in Section 2.02(a)(i).

“**Business Day**” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by law to be closed in Seattle, Washington.

“**Closing**” has the meaning set forth in Section 2.01.

“**Closing Date**” has the meaning set forth in Section 2.01.

“**Confidential Information**” has the meaning set forth in Section 5.02(a).

“**Conveyance Documents**” has the meaning set forth in Section 2.02(a)(ii).

“**Disclosure Schedules**” has the meaning set forth in Section 5.11.

“**Excluded Assets**” has the meaning set forth in Section 1.01(b).

“**Excluded Liabilities**” has the meaning set forth in Section 1.03.

“**Final Order**” means an order of the Bankruptcy Court, or other court of competent jurisdiction, for which the time to appeal has expired and no appeal was

filed, or if an appeal was filed, it has not been stayed or has been dismissed or denied and the time for further appeal has expired or no right of further appeal exists.

“GAAP” means United States generally accepted accounting principles.

“Governmental Entity” means any governmental regulatory authority or agency (whether U.S., federal, state, local or foreign).

“Including” shall always be read as “including without limitation.”

“Intellectual Property” means all trademarks, service marks, trade names, logos, domain names, computer software, mask work, invention, patent, trade secret, copyright, Internet, technology, processes, inventions, proprietary data, formulae, research and development data, computer software programs, know-how (including any registrations or applications for registration of any of the foregoing) or any other similar type of proprietary intellectual property right, in each case, that are used in or relate to the conduct of the Business.

“Inventory” means all of Seller’s inventory held for resale and all of Seller’s raw materials, work in process, finished products, wrapping, supply and packaging items and similar items with respect to the Business, in each case wherever the same may be located.

“Laboratory Operations” means the business of operating of a pharmacogenomics testing laboratory, similar to the revenue-generating business in which Seller was engaged.

“Material Adverse Effect” means any event, condition or matter that in the aggregate will result in or have a material adverse effect on the Acquired Assets, the Assumed and Assigned Contracts, the Assumed Liabilities, the value or prospects of the Business, or the ability of Purchaser to operate the Business after the Closing.

“Permits” means any permit, license or authorization issued, granted or given or otherwise made available by any Governmental Entity.

“Person” means an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.

“Petition Date” has the meaning set forth in the Recitals.

“Plan” has the meaning set forth in the Recitals.

“Purchase Price” has the meaning set forth in Section 1.04.

“Purchaser” has the meaning set forth in the Preamble.

“Sale Order” has the meaning set forth in Section 6.01(a).

“Seller” has the meaning set forth in the Preamble.

[Signatures on following page]

Asset Purchase Agreement Signature Page

IN WITNESS WHEREOF, Seller and Purchaser have caused this Agreement to be executed on their behalf by their officers thereunto duly authorized, as of the date first above written.

SELLER:

NATURAL MOLECULAR TESTING
CORPORATION

By: _____
Mark Calvert, solely in his capacity as court
appointed trustee for Natural Molecular
Testing Corporation

PURCHASER:

MEDTECH NATIONAL, INC.,
a Washington corporation

By: _____
Kirk St. Johns, Its Principal

EXHIBIT A

ACQUIRED ASSETS

115286-0001/LEGAL124787793.3

Exhibit A-1: Acquired Assets in Possession of Autogenomics, Inc.



Item No.	Quantity	Description	Photo
1	1	Autogenomics Analyzer	
2	14	Eppendorf Master Cyclers	
3	1	Eppendorf Master Cycler Controller	
4	3	Eppendorf Master Cyclers	
5	1	HiTech Universal Centrifuge	
6	1	Eppendorf Centrifuge	
7	1	-20 Degree Freezer	

Exhibit A-1: Acquired Assets in Possession of Autogenomics, Inc.





Item No.	Quantity	Description	Photo
8	1	Fridge / Freezer	
9	1	Fridge / Freezer	
10	1	-20 Degree Freezer	
11	1	-20 Degree Freezer	
12	1	-20 Degree Freezer	
14	1	Elga Purelab flex Water System	
15	1	Eppendorf Centrifuge	

Exhibit A-1: Acquired Assets in Possession of Autogenomics, Inc.






Item No.	Quantity	Description	Photo
16	1	Maxwell 16 Extractor	
17	1	Maxwell 16 Extractor	
18	1	Eppendorf Microcentrifuge 5430	
19	1	BioMac FX Liquid Handler	
20	1	Beckman FX Stacker	
21	1	FX Stacker - Vacuum Pump	
22	1	PCR Hood	

Exhibit A-1: Acquired Assets in Possession of Autogenomics, Inc.

Item No.	Quantity	Description	Photo
23	1	-20 Degree Freezer	
24	1	Eppendorf Centrifuge	
25	1	Eppendorf EP Motion Liquid Handler	
26	1	-20 Degree Freezer	

#27 1 Beckman Coulter Robot

#28 1 Beckman Coulter Tower


MARK CALVERT



K. St. Johns
Medtech National

Exhibit A-2: Acquired Assets in Possession of Trustee

Location:

Storage One at Benson

10650 SE 174th Street

Renton, Washington 98055

Units: 1098, 2031, 2033, 2035, 2041

Monthly rent equals \$212 per unit (\$1,060 in total)

Item	Approx. Quantity
Office chairs	40
Tables and Benches	12
Filing cabinets	5
Office cubicle walls	-
Shelving	-
Desks	5
Ovens	3
Office kitchen equipment - coffee machines etc.	-
Desktop computers with monitors, keyboards	20
Printers and copy machine	5
Lab supplies	-
Phone systems	45

EXHIBIT B

EXCLUDED ASSETS

All other assets not specifically identified on Exhibit A.

Exhibit B: Assets Excluded from Asset Sale

Item	Quantity
Roche Magna Pure Extractor (unless added to Acquired Assets by separate order)	1
Commercial Glass Door Cooler (sold)	2
Refrigerator (sold)	1
Four -20 Degree Freezers with genetic samples	4
Files and records located in storage unit (to be removed by Cascade Capital Group)	-
Desktop computers, software and Intellectual Property related to YourCode	8
All other assets of Seller not specifically listed on Exhibit A-1 or A-2	

EXHIBIT C

ASSUMED LIABILITIES

Storage Contract obligations accruing from February 19, 2015 forward with Storage One at Benson, 10650 SE 174th Street, Renton, Washington 98055

Units: 1098, 2031, 2033, 2035, 2041

Monthly rent equals \$212 per unit (\$1,060 in total)

EXHIBIT D

BILL OF SALE

FOR GOOD AND VALUABLE CONSIDERATION, receipt of which is hereby acknowledged, Mark Calvert, in his capacity as court-appointed bankruptcy trustee for Natural Molecular Testing Corporation ("Seller"), the debtor in the bankruptcy case now pending before the United States Bankruptcy Court for the Western District of Washington, under Case No. 13-19298-MLB, does hereby give, grant, bargain, sell, transfer, assign, convey and deliver to MedTech National, Inc., a Washington corporation ("Buyer"), pursuant to that certain Asset Purchase Agreement (the "Agreement"), dated January _____, 2015 the Acquired Assets identified in Section 1.01 of the Agreement.

This sale and conveyance is made pursuant to that certain Order of the Bankruptcy Court, dated _____, 2015, approving the Agreement and authorizing the transactions thereunder. The sale and conveyance is made from Seller to Buyer "as is, where is," with all faults and without warranties, representations or covenants whatsoever, whether express, implied or statutory, as to condition, quality or fitness for a particular purpose or use.

Dated as of _____, 2015.

NATURAL MOLECULAR TESTING
CORPORATION

By: _____
Mark Calvert, solely in his capacity as court-appointed trustee for Natural Molecular Testing Corporation

Schedule 1.04(b)

Note Amortization Schedule

MedTech National Inc.
Note Payable to NMTC
Base Upon Court Approval of Sale of Assets

Major Assumptions		#	Month	Beginnin g Balance	Interest	Payment	Ending Balance
Start Date of Note	2/1/2015	1	February	\$285,000	\$1,425	\$0	\$286,425
Note Rate	6.0%	2	March	\$286,425	\$1,432	\$0	\$287,857
Note Amount	\$310,000	3	April	\$287,857	\$1,439	\$0	\$289,296
Less Down Payment	(\$25,000)	4	May	\$289,296	\$1,446	(\$8,500)	\$282,243
Starting Note Balance	\$285,000	5	June	\$282,243	\$1,411	(\$8,500)	\$275,154
Monthly Payment	\$8,500	6	July	\$275,154	\$1,376	(\$8,500)	\$268,030
Start Date of Payment	5/30/2015	7	August	\$268,030	\$1,340	(\$8,500)	\$260,870
		8	September	\$260,870	\$1,304	(\$8,500)	\$253,674
		9	October	\$253,674	\$1,268	(\$8,500)	\$246,443
Start date is dependent on Court approval of this sale before 2/1/2015		10	November	\$246,443	\$1,232	(\$8,500)	\$239,175
		11	December	\$239,175	\$1,196	(\$8,500)	\$231,871
		12	January	\$231,871	\$1,159	(\$8,500)	\$224,530
		13	February	\$224,530	\$1,123	(\$8,500)	\$217,153
		14	March	\$217,153	\$1,086	(\$8,500)	\$209,739
		15	April	\$209,739	\$1,049	(\$8,500)	\$202,287
		16	May	\$202,287	\$1,011	(\$8,500)	\$194,799
		17	June	\$194,799	\$974	(\$8,500)	\$187,273
		18	July	\$187,273	\$936	(\$8,500)	\$179,709
		19	August	\$179,709	\$899	(\$8,500)	\$172,108
		20	September	\$172,108	\$861	(\$8,500)	\$164,468
		21	October	\$164,468	\$822	(\$8,500)	\$156,791
		22	November	\$156,791	\$784	(\$8,500)	\$149,074
		23	December	\$149,074	\$745	(\$8,500)	\$141,320
		24	January	\$141,320	\$707	(\$8,500)	\$133,526
		25	February	\$133,526	\$668	(\$8,500)	\$125,694
		26	March	\$125,694	\$628	(\$8,500)	\$117,823
		27	April	\$117,823	\$589	(\$8,500)	\$109,912
		28	May	\$109,912	\$550	(\$8,500)	\$101,961
		29	June	\$101,961	\$510	(\$8,500)	\$93,971
		30	July	\$93,971	\$470	(\$8,500)	\$85,941
		31	August	\$85,941	\$430	(\$8,500)	\$77,871
		32	September	\$77,871	\$389	(\$8,500)	\$69,760
		33	October	\$69,760	\$349	(\$8,500)	\$61,609
		34	November	\$61,609	\$308	(\$8,500)	\$53,417
		35	December	\$53,417	\$267	(\$8,500)	\$45,184
		36	January	\$45,184	\$226	(\$8,500)	\$36,910
		37	February	\$36,910	\$185	(\$8,500)	\$28,594
		38	March	\$28,594	\$143	(\$8,500)	\$20,237
		39	April	\$20,237	\$101	(\$8,500)	\$11,838
		40	May	\$11,838	\$59	(\$8,500)	\$3,398
		41	June	\$3,398	\$17	(\$3,415)	\$0